New findings from the RESHAW (Resveratrol Supporting Healthy Aging in Women) clinical study, shows that daily supplementation with the branded resveratrol, Veri-te, supports cognitive health in postmenopausal women.
Photo © iStockphoto.com/Jacob Wackerhausen
New findings1 from the RESHAW (Resveratrol Supporting Healthy Aging in Women) clinical study, shows that daily supplementation with the branded resveratrol Veri-te (Evolva; Reinach, Switzerland) supports cognitive health in postmenopausal women. In the 24-month randomized, placebo-controlled crossover trial, 125 postmenopausal women between the ages of 45 and 85 took either75 mg of resveratrol or placebo twice daily for 12 months, then crossed over the alternative for another 12 months. Results showed that compared to placebo, supplementation with resveratrol significantly increased overall cognitive performance by 33%.
Compared to women below the age of 65, women aged 65 years and older saw a relative improvement in verbal memory following supplementation with resveratrol. More specifically, improvements of verbal memory were 76% greater in women postmenopausal for more than 10 years compared to those postmenopausal for less than 10 years. A 12% improvement of cerebrovascular responsiveness (CVR) to hypercapnia, and 7% improvement of overall neurovascular coupling was also observed.
“What’s really powerful about these results is that the researchers also reported that 88% of the women stated that they would be likely to continue with resveratrol supplementation after the conclusion of the study” said Clare Panchoo, vice president, Health Ingredients, Evolva, in a press release. Furthermore, “the RESHAW exit survey details that more than half the women in the study reported that their perceived memory, mood and other aspects of living were improved with the supplementation,” added Panchoo. “We can foresee that these significant health outcomes observed in postmenopausal women, after supplementation of 75 mg of resveratrol twice a day, will be quickly translated into new product development and ultimately fulfill the gap in this underserved market segment.”
Previously published findings also showed improvements in cognitive health as well as bone mineral density.
Reference
Nutritional Outlook's Women in Nutraceuticals Roundtable: The Future of Women's Health Research
July 19th 2024Watch "The Future of Women's Health Research," a roundtable discussion presented by Nutritional Outlook in partnership with Women in Nutraceuticals. This roundtable is supplement to a recent article commissioned by WIN and published by Nutritional Outlook, titled “Taking Initiative: Can the WHI’s model help the nutraceutical industry answer questions the study didn’t even ask?”
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.